trial · primary record
CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16
HPV 16+ Recurrent or Metastatic Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2026-12-01 |
| Primary endpoint | Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 |
| Registry ID | NCT04713046 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:05.000Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04713046
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.